Elsevier

Resuscitation

Volume 30, Issue 1, August 1995, Pages 3-14
Resuscitation

Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies

https://doi.org/10.1016/0300-9572(95)00868-TGet rights and content

Abstract

Recent case reports have evidenced a temporal association between administration of i.v. magnesium sulfate (M) and resuscitation from prolonged cardiac arrest refractory to standard (S) ACLS attempts. However, speculation has arisen that M as a vasodilator, may decrease aortic diastolic and coronary perfusion pressure (CPP), aortic systolic and cerebral perfusion pressures (CePP), which may decrease resuscitation rates and neurologic recovery, as compared to standard ACLS alone (SA). Objective: To resolve positive beginning evidence vs. negative theory, we conducted a pilot study of M+S vs. SA in refractory cardiac arrest on resuscitation rates (% R, return of stable pulses > 30 min without CPR, first in-hospital cardiac arrest > 5-min duration) and neurologic recovery/survival to hospital discharge (SHD). Methods: All patients from 1 January 1990, 31 December 1991 at Rose Hospital, in cardiac arrest refractory to S through the first epinephrine dose (including 3 defibrillation attempts with pulseless VTVF) were included in the data analysis, except: (1) patients with trauma, known poisoning, < 18 years, pregnancy excluded; (2) Standard ACLS alone patients with cardiac arrest < 5-min duration were not included in the SA comparison group, because the shortest cardiac arrest time before i.v. MgSO4 administration in the M+S group was 5 min. M+S (N = 29) and SA (N = 33) groups were also comparable on mean age (72–73 years) in this open-label prospective case-matched control group study. Results: SHD rates were nearly equivalent between M+S (5.2%) and SA (4.5%). Complete or partial neurologic recovery, as best neurologic status post-R, occurred in 21% (629) M+S patients vs. 9% (333) SA (P = 0.17), even though cardiac arrest time on the study code call for resuscitated patients averaged shorter with SA (14.2 min) than M+S (19.8 min). M was frequently administered late in the resuscitation attempt — code call to M administration averaged 16.5 min (< 10 min in only 428 patients). A trend toward increased % R with M was evidenced: 21% (733) SA vs. 35% (1029) M+S (P = 0.21). A temporal association between M administration and first return of spontaneous circulation (ROSC) was also documented in 4 of 10 M+S patients (pulseless electrical activity (3)/pulseless VT (1)), who had first ROSCR occur within 0.5–2.25 min following first i.v. M bolus delivery, after 11–30 min (mean = 20 min) of continuous pulseless rhythm refractory to standard ACLS. All M+S resuscitations occurred within the dose range 2.5–5 g (i.v. push): 36 (50%) and 713 (54%) R occurred with 1–3 g and 4–5 g MgSO4, respectively (at least 1113 patients had peripheral i.v. delivery with 4–5 g M). Analyzing post-ROSC hypotension proved important, as 50% of pts with first recorded systolic BP post-ROSC < 90 mmHg were resuscitated vs. 83% with > 90 mmHg (P = 0.10). A trend toward increased post-ROSC hypotension was evidenced with i.v. MgSO4: Recorded first or second systolic BP < 90 mmHg post-ROSC occurred in 66% of M+S vs. 42% of SA patients. All 3 M+S patients having a wide open i.v. levophed infusion as vasopressor support, started immediately post-ROSC/i.v. MgSO4 with systolic BP < 90 mmHg and continued at least 15 min (titrating to a systolic BP ~ 110 mmHg), had a temporal association between M delivery and R after 14–30 min of continuous pulselessness refractory to S. Conclusion: Human research determining whether i.v. MgSO4 increases long-term survival from refractory cardiac arrest should be vigorously pursued, as it is safe to proceed given the above described considerations.

Cited by (61)

  • The Pharmacologic Management of Cardiac Arrest

    2023, Emergency Medicine Clinics of North America
  • Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review

    2018, Resuscitation
    Citation Excerpt :

    All but one observational study administered the intervention drug during CPR while one administered the drug immediately after ROSC. The time from cardiac arrest to first dose of the trial drug was reported in six studies [51–54,57,59] and ranged from 6 to 35 min. Additional information on the characteristics of included studies can be found in Supplemental File 2.

  • European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support

    2010, Resuscitation
    Citation Excerpt :

    A further dose of 150 mg may be given for recurrent or refractory VF/VT, followed by an infusion of 900 mg over 24 h. Lidocaine, 1 mg kg−1, may be used as an alternative if amiodarone is not available, but do not give lidocaine if amiodarone has been given already. The routine use of magnesium in cardiac arrest does not increase survival.287–291 and is not recommended in cardiac arrest unless torsades de pointes is suspected (see peri-arrest arrhythmias).

View all citing articles on Scopus
View full text